Literature DB >> 19243302

Matriptase: a culprit in cancer?

Karin List1.   

Abstract

Pericellular proteases can degrade extracellular matrix proteins and reshape their microenvironment, as well as cleave and activate signaling molecules such as growth factors and their receptors. In this capacity, pericellular proteolysis is essential for multiple biological processes, including development, tissue homeostasis and tissue repair. On the flip side, dysregulated pericellular proteolysis is a hallmark in many pathological conditions including cancer, and is believed to be critically involved in tumor growth, invasion and dissemination of cancer cells to other organs. Matriptase is a member of the family of Type II transmembrane serine proteases, and has been implicated in a variety of epithelial cancers. This review summarizes current knowledge about matriptase and its role in cancer based on expression studies, biochemical characterization, cell-culture based studies and in vivo experiments.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19243302     DOI: 10.2217/14796694.5.1.97

Source DB:  PubMed          Journal:  Future Oncol        ISSN: 1479-6694            Impact factor:   3.404


  35 in total

1.  Targeting zymogen activation to control the matriptase-prostasin proteolytic cascade.

Authors:  Zhenghong Xu; Ya-Wen Chen; Aruna Battu; Paul Wilder; David Weber; Wenbo Yu; Alexander D Mackerell; Li-Mei Chen; Karl X Chai; Michael D Johnson; Chen-Yong Lin
Journal:  J Med Chem       Date:  2011-10-12       Impact factor: 7.446

2.  Differential tumorigenic potential and matriptase activation between PDGF B versus PDGF D in prostate cancer.

Authors:  Abdo J Najy; Joshua J Won; Lisa S Movilla; Hyeong-Reh C Kim
Journal:  Mol Cancer Res       Date:  2012-06-11       Impact factor: 5.852

Review 3.  Roles of Grainyhead-like transcription factors in cancer.

Authors:  S M Frisch; J C Farris; P M Pifer
Journal:  Oncogene       Date:  2017-07-17       Impact factor: 9.867

4.  Matriptase activation and shedding through PDGF-D-mediated extracellular acidosis.

Authors:  Abdo J Najy; Gregory Dyson; Bhanu P Jena; Chen-Yong Lin; Hyeong-Reh C Kim
Journal:  Am J Physiol Cell Physiol       Date:  2015-07-08       Impact factor: 4.249

5.  Blocking the proteolytic activity of zymogen matriptase with antibody-based inhibitors.

Authors:  Trine Tamberg; Zebin Hong; Daphné De Schepper; Signe Skovbjerg; Daniel M Dupont; Lars Vitved; Christine R Schar; Karsten Skjoedt; Lotte K Vogel; Jan K Jensen
Journal:  J Biol Chem       Date:  2018-11-08       Impact factor: 5.157

6.  Laminin-332 cleavage by matriptase alters motility parameters of prostate cancer cells.

Authors:  Manisha Tripathi; Alka A Potdar; Hironobu Yamashita; Brandy Weidow; Peter T Cummings; Daniel Kirchhofer; Vito Quaranta
Journal:  Prostate       Date:  2011-02-01       Impact factor: 4.104

7.  Design and synthesis of potent, selective inhibitors of matriptase.

Authors:  Eloïc Colombo; Antoine Désilets; Dominic Duchêne; Félix Chagnon; Rafael Najmanovich; Richard Leduc; Eric Marsault
Journal:  ACS Med Chem Lett       Date:  2012-04-11       Impact factor: 4.345

8.  Matriptase-mediated cleavage of EpCAM destabilizes claudins and dysregulates intestinal epithelial homeostasis.

Authors:  Chuan-Jin Wu; Xu Feng; Michael Lu; Sohshi Morimura; Mark C Udey
Journal:  J Clin Invest       Date:  2017-01-17       Impact factor: 14.808

9.  Inhibitors of HGFA, Matriptase, and Hepsin Serine Proteases: A Nonkinase Strategy to Block Cell Signaling in Cancer.

Authors:  Zhenfu Han; Peter K W Harris; Darin E Jones; Ryan Chugani; Tommy Kim; Manjula Agarwal; Wei Shen; Scott A Wildman; James W Janetka
Journal:  ACS Med Chem Lett       Date:  2014-10-09       Impact factor: 4.345

10.  Crystal structures of matriptase in complex with its inhibitor hepatocyte growth factor activator inhibitor-1.

Authors:  Baoyu Zhao; Cai Yuan; Rui Li; Dan Qu; Mingdong Huang; Jacky Chi Ki Ngo
Journal:  J Biol Chem       Date:  2013-02-26       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.